Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Case ID:
TAB-2617
Web Published:
12/6/2022
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels within tumors. While in some cases cancer cells are also killed by the tumor-targeted toxin, the primary mechanism of action is thought to be a decrease in blood flow to the center of tumors, causing cancer cell death and tumor necrosis. Preliminary and on-going studies have demonstrated that the targeted toxins have antitumor effects on melanomas, lung cancers and colon cancer in mouse models, and on feline and canine oral tumors. Interestingly, this therapy does not target a specific type of cancer cell, rather it targets the vasculature in and around tumors. Therefore, it has great potential to treat a wide range of solid tumors. Additionally, because few non-surgical treatments are available to treat many human and veterinary solid tumors, this technology would fill an unmet need in cancer therapy.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Human_and_Veterinary_Cancer_ Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_Technology
Keywords:
Anthrax
AnthraxToxins
CB1BXX
CB1XXX
CB3CXX
CB3XXX
CBXXXX
CXXXXX
fusion proteins
Patent Category - Biotechnology
THERAPY
toxin
tumor
Bookmark this page
Download as PDF
For Information, Contact:
Wade Green
Lead Technology Transfer and Patent Specialist
NIH Technology Transfer
wade.green@nih.gov